PET Tau Imaging for Neurodegenerative Diseases
This study is looking at how well a special imaging agent, 18F-AV-1451, can detect a protein called tau in the brain. Tau is known to build up in people with brain cell damage, including those with neurodegenerative diseases like Alzheimer's and Parkinson's. Researchers want to see if 18F-AV-1451 can help doctors better understand and diagnose these conditions. You might be able to join if you are 18 or older and have been diagnosed with a neurodegenerative disease such as FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS, or FTD-ALS. The study aims to measure regional tau uptake over 10 years. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 300 participants. It uses a specialized radioactive PET tracer, 18F-AV-1451, to detect tau proteins.
- What's involved
- Participants will undergo a baseline 18F-AV-1451 brain scan. The results will be compared with other information like MRI, spinal fluid, and cognitive tests.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for regional uptake measurements for 10 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PET Tau - Neurodegenerative Disease Imaging
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- David Irwin, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Regional uptake10 years
Examine regional anatomic distribution of PET-tau uptake comparatively in dementia syndromes and PET-Tau uptake with neuropsychology and MRI regional GM atrophy at baseline collected under other center protocols. Uptake with neuropsychology and MRI regional GM atrophy at baseline.